For some time, real world evidence (RWE) has been discussed as the remedy for many difficulties companies face when trying to get drugs to market. So far the field is not as developed as it could be but advances are coming with the increasing digitization of real world data (RWD) sources. Scrip takes a look at the opportunities and challenges and how companies should plan their strategies.
RWE has been around for some time and is increasingly used to supplement both regulatory approval packages and pricing and...